Pharma

Contingent Workforce Management Market to Reach $465.2 trillion, Globally, by 2031 at 10.5% CAGR: Allied Market Research

Retrieved on: 
Thursday, March 2, 2023
Telecom, Permanent, Excludability, Final good, AI, PDF, Government, Employment, BFSI, Table, Morale, Workforce, COVID-19, Real estate, Growth, Health, Education, Pharma, Transport, Retail, Construction, Health care

PORTLAND, Ore., March 2, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "Contingent Workforce Management Market By Type (Permanent Staffing, Flexible Staffing), By End-user Industry (IT and Telecom , BFSI , Healthcare , Manufacturing- Automotive, Business/Professional Service, Retail trade, Pharma/biotech/medical equip, Manufacturing- Consumer Products, Government (Excluding Education), Transportation/warehousing/packaging, Manufacturing-Others, Real Estate and rental leasing, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031." According to the report, the global contingent workforce management industry generated $171.5 trillion in 2021 and is estimated to reach $465.2 trillion by 2031 witnessing a CAGR of 10.5% from 2022 to 2031. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chains, regional landscapes, and competitive scenarios.

Key Points: 
  • " According to the report, the global contingent workforce management industry generated $171.5 trillion in 2021 and is estimated to reach $465.2 trillion by 2031 witnessing a CAGR of 10.5% from 2022 to 2031.
  • Rising population, increasing demand for flexible workforces, shifting demographics, and labor force participation rates drive the growth of the global contingent workforce management market.
  • However, the emergence of AI will present new growth opportunities for the global contingent workforce management market in the coming years.
  • The COVID-19 pandemic had a negative impact on the contingent workforce management industry because of the layoffs in various companies.

NEURELIS WINS 2023 PM360 PHARMA CHOICE MULTICHANNEL GOLD AWARD FOR 'GIVE SEIZURES THE SPRAYER' MARKETING CAMPAIGN

Retrieved on: 
Thursday, March 2, 2023
Overalls, CIV, Quality of life, FDA, Sprayer, Epilepsy, Patient, Health, Heart, Imagination, Regulation of tobacco by the U.S. Food and Drug Administration, Frustration, Food, Pharma, Pharmaceutical industry, Marketing, Gustav Neuring

'Give Seizures the Sprayer', marketing campaign led by Beth Henriksen, Director of Marketing, Neurelis, Inc., wins the 2023 PM360 Pharma Choice Multichannel Gold Award

Key Points: 
  • 'Give Seizures the Sprayer', marketing campaign led by Beth Henriksen, Director of Marketing, Neurelis, Inc., wins the 2023 PM360 Pharma Choice Multichannel Gold Award
    SAN DIEGO, March 2, 2023 /PRNewswire/ -- Neurelis, Inc. is proud to announce the 'Give Seizures the Sprayer' marketing campaign for VALTOCO® (diazepam nasal spray) CIV has won a 2023 PM360 Pharma Choice Multichannel Gold Award.
  • PM360, a leading health and life sciences marketing industry trade magazine, established the Pharma Choice Awards to honor the year's best creative campaigns and marketing initiatives from the life sciences industry.
  • More than 8,500 votes were cast for the 13th Annual PM360 Pharma Choice Awards .
  • We all understand the work that goes into campaign development and the goal to be both differentiated and authentic," said Beth Henriksen, Director of Marketing, Neurelis.

Quris-AI Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2023

Retrieved on: 
Thursday, March 2, 2023
NASA, Early stage innovation company, Drug development, Patient, Human body, Liver, Organization, Merck Group, Editorial, MrBeast, Research, ITunes, Pharma, Partnership, Pharmaceutical industry, Cryptocurrency

BOSTON and TEL-AVIV, Israel, March 02, 2023 (GLOBE NEWSWIRE) -- Quris-AI , has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2023.

Key Points: 
  • BOSTON and TEL-AVIV, Israel, March 02, 2023 (GLOBE NEWSWIRE) -- Quris-AI , has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2023.
  • In addition to the World’s 50 Most Innovative Companies, 540 organizations are recognized across 54 sectors and regions.
  • Fast Company will host its third annual Most Innovative Companies Summit on April 19 and 20.
  • Fast Company’s Most Innovative Companies issue (March/April 2023) is available online here , as well as in-app form via iTunes, and on newsstands beginning March 14.

Asia Pharmaceutical Regulatory Affairs Training Course: Opportunities and Challenges to those Wishing to Work in the Region (October 11-13, 2023)

Retrieved on: 
Wednesday, March 1, 2023
Pharmaceutics, Allen & Hanburys, Active ingredient, GSK plc, Foreign, Commonwealth and Development Office, Roche, DRA, University of Basel, Publication, Pharma, Head, WHO, London Organising Committee of the Olympic and Paralympic Games, Pharmaceutical formulation, University of Strathclyde, University of Manchester, Textbook, Biochemistry, Editorial board, Novartis, Pharmaceutical industry, Medtech, Pharmacy, Chemistry

Dr Alan Chalmers is a pharmacist with over 35 industrial experiences mainly in the field of pharmaceutical regulatory affairs.

Key Points: 
  • Dr Alan Chalmers is a pharmacist with over 35 industrial experiences mainly in the field of pharmaceutical regulatory affairs.
  • He has also been director of two UK and Swiss registered pharmaceutical companies with specialised responsibility for international regulatory strategy.
  • He is published, and his publications include a textbook on International Pharmaceutical Registration, Active Pharmaceutical Ingredients and as Swiss correspondent to the Regulatory Affairs Journals Pharma and Medtech.
  • Since 2012 he has been a member of the Editorial Board, Scrip Regulatory Affairs.

MediPharm Labs Provides Update on Clinical Trial Progress Including FDA Approval of Partner Study

Retrieved on: 
Wednesday, March 1, 2023
Clinical trial, DEL, CTM, Drug development, GMP, Research, FDA, Pharma, Health Canada, API, Cannabis, Pharmaceutical industry

CTM shipment in Q1 2023

Key Points: 
  • CTM shipment in Q1 2023
    In addition to these institutionally led studies, the Company is also providing API and clinical trial material to various pharmaceutical companies for commercial projects involving cannabis-derived drugs.
  • The timelines for both institutional and industry research are long by nature with positive outcomes uncertain.
  • MediPharm has been selected by these researchers based on the US and Canadian Regulatory requirements for pharmaceutical GMP manufactured clinical trial materials.
  • David Pidduck, CEO, MediPharm Labs commented, "Commitment to pharmaceutical cannabis research has been a founding principle of the company since its inception.

Fulgent Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Tuesday, February 28, 2023
Biotechnology, Infectious Diseases, Health, Genetics, Oncology, NGS, EBITDA, Depreciation, COVID-19 testing, Medicine, GAAP, Acquisition, Investment, Growth, Laboratory, Table, Pathology, Battle of Saint-Fulgent, COVID-19, COVID, Pharmaceutical industry, Bank, Beauty salon, Pharma

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”, or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its fourth quarter and full year ended December 31, 2022.

Key Points: 
  • Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”, or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its fourth quarter and full year ended December 31, 2022.
  • Non-GAAP income (loss), non-GAAP income (loss) per share, and adjusted EBITDA income (loss) are described below under “Note Regarding Non-GAAP Financial Measures” and are reconciled to the most directly comparable GAAP financial measure, GAAP income (loss), in the accompanying tables.
  • Certain information set forth in this press release, including non-GAAP income (loss), non-GAAP income (loss) per share, and adjusted EBITDA income (loss) are non-GAAP financial measures.
  • Management uses these non-GAAP financial measures along with the most directly comparable GAAP financial measure of net income (loss) in evaluating the Company's operating performance.

TheMathCompany Features in Everest Group’s Analytics and AI Services Specialists PEAK Matrix® Assessment 2022

Retrieved on: 
Tuesday, February 28, 2023
Software, Technology, Artificial Intelligence, Data Management, Marketing, Organizational founder, Intelligence, Information technology, Star, Contender, Investment, Consultant, Growth, PEAK, Pharma, Information services, IP, USD, Sales, EU

TheMathCompany , Illinois-headquartered leading global data analytics and engineering firm, announced that it has emerged as a Major Contender in Everest Group’s Analytics and AI Services Specialists PEAK Matrix® Assessment 2022.

Key Points: 
  • TheMathCompany , Illinois-headquartered leading global data analytics and engineering firm, announced that it has emerged as a Major Contender in Everest Group’s Analytics and AI Services Specialists PEAK Matrix® Assessment 2022.
  • The company was also conferred a Star Performer title for demonstrating the most improvement over time on the PEAK Matrix®.
  • This report was conducted via multiple interactions with leading analytics and Al services specialists, client reference checks, and an ongoing analysis of the analytics and Al services market.
  • Anuj Krishna, Co-founder & Chief Product Officer, TheMathCompany, said, “Enterprises are seeking partners that enable their analytics & AI programs to be more self-sufficient.

Actylis Opens A 30,000ft2 cGMP Facility to Bolster its Innovative API Manufacturing Capabilities

Retrieved on: 
Monday, February 27, 2023
Chemicals, Plastics, Other Communications, Manufacturing, University, Pharmaceutical, Education, Communications, Transport, Clinical Trials, Other Manufacturing, Science, Logistics, Supply Chain Management, Other Science, Health, Research, Clinical trial, BCA, GMP, ISO, API, Coffman engine starter, R, Fine chemical, Pharma

Our intimate knowledge of their needs, our consultative approach, and focus on innovation offer unparalleled choice and flexibility.

Key Points: 
  • Our intimate knowledge of their needs, our consultative approach, and focus on innovation offer unparalleled choice and flexibility.
  • We have 7 manufacturing suites and our clean rooms will be ISO Class 8 compliant by Q3.
  • The new facility is a 10 minute drive from our R&D facility which is critical for scaling and developing new processes for the plant.
  • Its capabilities encompass the entire R&D, product development and manufacturing spectrum, including technical sales support, R&D, manufacturing and production, quality, supply chain, global sourcing, and regulatory compliance.

EQS-News: DEFENCE’S PIPELINE ADVANCES TO MULTIPLE PHASE I CLINICAL TRIALS

Retrieved on: 
Monday, February 27, 2023
Quality control, Cell division, Safety, Therapy, ARM, Breast cancer, Mouse, News, Protein, Cancer, Survival, DNA, Dog, A1, Cervical cancer, MTD, Spacecraft, Partnership, IND, GLP, City of Hope, Survival rate, Standard of care, Breast, Patient, City, Vaccination, Growth, Quality control in tissue engineering, Cell death, E7, ADC, HPV, Messenger, Cell proliferation, Animal, Cytoplasm, Melanoma, Neoplasm, DNA replication, Rat, Prevalence, Lung cancer, Radical, Vaccine, Pharma, Defense

Over the last three years, Defence has been heavily active in developing its AccumTM-based platform pipeline.

Key Points: 
  • Over the last three years, Defence has been heavily active in developing its AccumTM-based platform pipeline.
  • Defence initiated the manufacturing of its ARM vaccine in Q1 of 2023 with the objective to start treating patients with solid tumors in a Phase I clinical trial by Q4 of 2023.
  • This milestone shall be followed by IND package filing to obtain approval for initiating a Phase I clinical trial against lung cancer.
  • The objective is to begin GLP studies in 2023 prior to IND package filing for initiating a Phase I clinical trial against breast cancer.

Zealand Pharma to Host Conference Call on March 2, 2023 at 2 pm CET (8 am ET) to Present Full Year Results for 2022

Retrieved on: 
Friday, February 24, 2023
CET, Pharma, Webcast, Zealand Pharma, Q&A, Conference, Pharmaceutical industry

Zealand Pharma to Host Conference Call on March 2, 2023 at 2 pm CET (8 am ET) to Present Full Year Results for 2022

Key Points: 
  • Zealand Pharma to Host Conference Call on March 2, 2023 at 2 pm CET (8 am ET) to Present Full Year Results for 2022
    Copenhagen, Denmark February 24, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.
  • 20045078) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on March 2, 2023 at 2:00 pm CET (8:00 am ET) following the announcement of results for the full year of 2022.
  • Presenting during the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; and Chief Medical Officer, David Kendall.
  • The conference call will be conducted in English.